Bicycle Therapeutics plc (NASDAQ:BCYC) CFO Sells $19,655.55 in Stock

Bicycle Therapeutics plc (NASDAQ:BCYC) CFO Alethia Young sold 1,395 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $19,655.55. Following the completion of the sale, the chief financial officer now owns 45,605 shares of the company’s stock, valued at $642,574.45. The trade was a 2.97 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Bicycle Therapeutics Stock Performance

BCYC stock opened at $15.14 on Wednesday. Bicycle Therapeutics plc has a fifty-two week low of $12.17 and a fifty-two week high of $28.67. The company has a market capitalization of $1.05 billion, a price-to-earnings ratio of -4.60 and a beta of 0.92. The business’s 50 day moving average price is $19.09 and its two-hundred day moving average price is $21.82.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.74) earnings per share for the quarter, topping the consensus estimate of ($0.78) by $0.04. The company had revenue of $2.68 million for the quarter, compared to analysts’ expectations of $6.82 million. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm’s revenue for the quarter was down 50.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.26) earnings per share. Sell-side analysts forecast that Bicycle Therapeutics plc will post -3.05 earnings per share for the current year.

Analyst Upgrades and Downgrades

BCYC has been the topic of several analyst reports. HC Wainwright decreased their target price on shares of Bicycle Therapeutics from $55.00 to $33.00 and set a “buy” rating on the stock in a research note on Monday, December 16th. Stephens assumed coverage on shares of Bicycle Therapeutics in a research report on Friday, November 8th. They issued an “equal weight” rating and a $25.00 price objective on the stock. B. Riley dropped their target price on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a report on Friday, December 13th. Needham & Company LLC restated a “buy” rating and set a $38.00 price target on shares of Bicycle Therapeutics in a report on Thursday, October 31st. Finally, JMP Securities dropped their price objective on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a report on Wednesday, December 18th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Bicycle Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $35.25.

Hedge Funds Weigh In On Bicycle Therapeutics

Several large investors have recently made changes to their positions in the business. Assetmark Inc. purchased a new position in Bicycle Therapeutics during the third quarter valued at $34,000. GAMMA Investing LLC grew its stake in shares of Bicycle Therapeutics by 105.1% in the third quarter. GAMMA Investing LLC now owns 2,026 shares of the company’s stock worth $46,000 after acquiring an additional 1,038 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Bicycle Therapeutics by 69.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,138 shares of the company’s stock valued at $162,000 after acquiring an additional 2,918 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Bicycle Therapeutics by 26.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock worth $191,000 after purchasing an additional 1,782 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in Bicycle Therapeutics in the 2nd quarter worth about $206,000. 86.15% of the stock is currently owned by hedge funds and other institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.